Pivotal Study Demonstrated the Combination More Than Doubled Progression-Free Survival Compared to Investigated SOCTHOUSAND OAKS, Calif., Jan. 17, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved LUMAKRAS® (sotorasib) in combination with Vectibix® (panitumumab) for the treatment of adult patients with KRAS G12C-mutated metastatic colorectal cancer (mCRC), as determined by an FDA-approved test, who have received prior fluoropyrimidine-, ox ...

Some investors believe you make money when you buy a stock, not when you sell it. The logic behind this idea is that investing in the right stock at the right time -- and holding onto it for a while -- is one of the best formulas for earning terrific returns.So, a company being near its 52-week low is no reason to avoid it. On the contrary, that might be the best time to invest, provided there are good reasons to believe it will bounce back.With that in mind, let's consider two stocks that haven't performed ...

The latest trading session saw Amgen (AMGN) ending at $267.10, denoting a -1.14% adjustment from its last day's close. The stock fell short of the S&P 500, which registered a gain of 0.12% for the day. At the same time, the Dow added 0.52%, and the tech-heavy Nasdaq lost 0.23%.The world's largest biotech drugmaker's stock has climbed by 1.38% in the past month, exceeding the Medical sector's loss of 2.25% and the S&P 500's loss of 3.45%.The investment community will be closely monitoring the performance of ...

For new and old investors, taking full advantage of the stock market and investing with confidence are common goals. Zacks Premium provides lots of different ways to do both.The popular research service can help you become a smarter, more self-assured investor, giving you access to daily updates of the Zacks Rank and Zacks Industry Rank, the Zacks #1 Rank List, Equity Research reports, and Premium stock screens.It also includes access to the Zacks Style Scores. What are the Zacks Style Scores? The Zacks Sty ...

Company Overview - Amgen is focused on serious diseases, particularly in four key areas: heart attack, stroke, cancer, osteoporosis, and rare diseases [3][4] - The company has a portfolio of 38 innovative and biosimilar medicines, each contributing significantly to addressing these serious diseases [4] Community Engagement - Amgen has committed $10 million to support the rebuilding efforts in Southern California following the devastating wildfires [3] Leadership and Presentation - Robert Bradway, Chairman, CEO & President of Amgen, presented at the 43rd Annual J.P. Morgan Healthcare Conference on January 13, 2025 [1][2]

Key Points Company and Industry Information 1. **Company**: Amgen Inc. (NASDAQ: AMGN) 2. **Event**: 43rd Annual J.P. Morgan Healthcare Conference 2025 3. **Date**: January 13, 2025 4. **Time**: 6:00 PM ET 5. **Participants**: - Robert Bradway - Chairman, CEO & President of Amgen - Chris Schott - JPMorgan Core Views and Arguments 1. **Focus on Serious Diseases**: Amgen is committed to addressing serious diseases, including heart attack, stroke, cancer, osteoporosis, and various rare diseases. 2. **Portfolio of Medicines**: The company has a portfolio of 38 innovative and biosimilar medicines, each contributing significantly to combating these diseases. 3. **Confidence in Growth Outlook**: Amgen is confident about the growth prospects of its business, driven by the quality of its medicine portfolio. Other Important Content 1. **Community Support**: Amgen expressed concern and solidarity with the community affected by wildfires in Southern California, committing to contribute $10 million to the rebuilding efforts. 2. **Company History**: Amgen has been based in Southern California for over 40 years.

43rd ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE ROBERT A. BRADWAY, CHAIRMAN AND CHIEF EXECUTIVE OFFICER January 13, 2025 This presentation includes GAAP and non-GAAP financial measures. In accordance with the requirements of SEC Regulation G, reconciliations between these two measures, if these slides are in hard copy, accompany the hard copy presentation or, if these slides are delivered electronically, are available on the Company's website at www.amgen.com within the Investors section. 2 Provided January 1 ...

THOUSAND OAKS, Calif., Jan. 8, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at the 2025 J.P. Morgan Healthcare Conference at 3:00 p.m. PT on Monday, January 13, 2025. Robert A. Bradway, chairman and chief executive officer at Amgen will present at the conference. The webcast will be broadcast over the internet simultaneously and will be available to members of the news media, investors and the general public.The webcast, as with other selected presentations regarding developments in Amgen's busines ...

My strategy as a dividend growth investor is to buy qualitative stocks with an adequate margin of safety. My reasoning is two-pronged: First, this can limit downside risk if black swan events materialize. Second, this approach allows me to secure greater starting income and providesHi, my name is Kody. Aside from my articles here on Seeking Alpha, I am also a regular contributor to TipRanks, Sure Dividend, and The Dividend Kings and iREIT+Hoya Capital. I have been investing since September 2017 and interest ...

Company Overview - Amgen Inc is a biotechnology company with a strong track record in developing and commercializing products in four main therapeutic areas: general medicine, rare disease, oncology, and inflammation/immunology [1] - The company reported a 24% revenue growth in its Q3 2024 financial report [1] Analyst Background - The analyst has a background in life sciences with a PhD in Bioengineering and over 20 years of experience in research and development of novel Cell & Gene Therapies (CGT) [1] - The analyst focuses on analyzing biotechnology, pharmaceutical, Medtech, and healthcare stocks, leveraging their expertise to assess the potential of novel treatments and their impact on shareholder returns [1] Disclosure and Position - The analyst holds a beneficial long position in Amgen Inc through stock ownership, options, or other derivatives [2] - The analyst wrote the article independently and is not receiving compensation for it other than from Seeking Alpha [2]